Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18405628 | 0.86 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL775846 | 0.81 | TSHR (0.44) | EPHX1CA1CA2ALDH1A1IDO1 | |
| SCHEMBL18406854 | 0.80 | ATM (0.41) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL17036710 | 0.80 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL18405631 | 0.79 | HCAR2 (0.45) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL9946240 | 0.78 | EPHX1 (0.46) | EPHX1RAB9ACA1CA2ALDH1A1 | |
| SCHEMBL18405626 | 0.77 | HCAR2 (0.39) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL18405627 | 0.76 | GRIA1 (0.43) | HCAR2KEAP1NFE2L2ATMMAPT | |
| SCHEMBL23963384 | 0.76 | EPHX1 (0.43) | EPHX1MAPTNPSR1CA1CA2 | |
| SCHEMBL15681507 | 0.76 | EPHX1 (0.43) | EPHX1CA1CA2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-05-28 | — | — | US | disclosed |
| US-20170129851-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-05-11 | — | — | US | disclosed |
| US-9604922-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-28 | — | — | US | disclosed |
| US-20150239829-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | SULT2A1, FH, STS | HCAR2 544/4885KEAP1 1735/4885NFE2L2 942/4885 |
| US-20170129851-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | SULT2A1, FH, STS | HCAR2 544/4885KEAP1 1735/4885NFE2L2 942/4885 |
| US-20150239829-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | SULT2A1, FH, STS | HCAR2 544/4885KEAP1 1735/4885NFE2L2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.